News Column

Investigators from Liaoning University Have Reported New Data on Bexarotene Therapy (Bexarotene nanocrystal-Oral and parenteral formulation...

July 30, 2014



Investigators from Liaoning University Have Reported New Data on Bexarotene Therapy (Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation)

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Drugs and Therapies have been published. According to news reporting out of Shenyang, People's Republic of China, by NewsRx editors, research stated, "Bexarotene (Targretin ) is a synthetic retinoid that selectively activates the retinoid X receptor subfamily of retinoid receptors and exhibits potent anti-tumor activity. However, the poor solubility and bioavailability limit its application."

Our news journalists obtained a quote from the research from Liaoning University, "The main aim of this study is to investigate the potential of oral and parenteral nanocrystals in enhancing the bioavailability of bexarotene. In this work, the orthogonal design was used to screen the optimum stabilizers and precipitation-combined microfluidization method was employed to obtain the optimal nanocrystals. According to DSC, X-ray diffraction analysis and Raman examination, the nanocrystals were still in crystalline state after the preparation procedure. By reducing the particle size, the in vitro dissolution rate of bexarotene was increased significantly. The in vivo test was carried out in rats and pharmacokinetic parameters of the bexarotene solution and bexarotene nanocrystals were compared after gavage and intravenous administration. The higher AUC and lower C-max indicated that oral bexarotene nanocrystals significantly increased the bioavailability of bexarotene and decreased its side effects."

According to the news editors, the research concluded: "Compared to the oral nanocrystals, the intravenous nanocrystals cut losses and increased bioavailability because of the absence of first pass effect and enterohepatic circulation."

For more information on this research see: Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 2014;87(1):160-169. European Journal of Pharmaceutics and Biopharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutics and Biopharmaceutics - www.elsevier.com/wps/product/cws_home/600120)

Our news journalists report that additional information may be obtained by contacting L.J. Chen, Liaoning Univ, Sch Pharmaceut Sci, Dept. of Pharmaceut, Shenyang 110036, People's Republic of China. Additional authors for this research include Y.J. Wang, J.Z. Zhang, L.L. Hao, H.J. Guo, H.X. Lou and D.R. Zhang (see also Drugs and Therapies).

Keywords for this news article include: Shenyang, People's Republic of China, Asia, Antineoplastics, Bexarotene, Drugs, Drugs and Therapies, Pharmaceuticals, Pharmacokinetics, Therapy

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters